A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel,
Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment
of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC)
Model and Conjunctival Allergen Provocation Test (CAPT) Model. Approximately 150 subjects
will be enrolled and randomized in one study center in Canada for a duration of 0.33 years.